# US 2013/0157924 A1 · Reducing transmission of sexually transmitted infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157924 A1
- Document ID: US20130157924A1
- Status: Published application
- Kind: A1
- Application number: 13/643,026
- Filed: 2011-04-22
- Published: 2013-06-20
- Earliest claimed: 2010-04-23
- Assignees: The Regents of the University of California; University of Rochester
- Inventors: Stephen Dewhurst; Bradley Nilsson; Joanna Olsen; Jerry Yang
- Web page: https://patentgrep.com/patent/US20130157924A1

## CPC

- A61K 31/428: condensed with carbocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are compositions and methods for treating or preventing a sexually transmitted infection in a subject.

## Claims

### Claim 1

A method of treating or preventing a sexually transmitted infection in a subject, the method comprising administering to the subject a semen-derived enhancer of viral infection (SEVI)-binding agent, wherein the agent comprises a compound of the following formula:
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R1, R2, R3, R4, R5, R6, R7, and R8 are each independently selected from hydrogen, halogen, hydroxyl, trifluoromethyl, substituted or unsubstituted thio, substituted or unsubstituted alkoxyl, substituted or unsubstituted aryloxyl, substituted or unsubstituted amino, substituted or unsubstituted C1-12 alkyl, substituted or unsubstituted C2-12 alkenyl, substituted or unsubstituted C2-12 alkynyl, substituted or unsubstituted C1-12 heteroalkyl, substituted or unsubstituted C2-12 heteroalkenyl, substituted or unsubstituted C2-12 heteroalkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
R9 and R10 are each independently selected from hydrogen, substituted or unsubstituted C1-20 alkyl, substituted or unsubstituted C2-20 alkenyl, substituted or unsubstituted C2-20 alkynyl, substituted or unsubstituted C1-20 heteroalkyl, substituted or unsubstituted C2-20 heteroalkenyl, substituted or unsubstituted C2-20 heteroalkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 2 (depends on 1)

The method of claim 1, wherein R3 is methyl.

### Claim 3 (depends on 1)

The method of claim 1, wherein R1, R2, R4, R5, R6, R7, and R8 are hydrogen.

### Claim 4 (depends on 1)

The method of claim 1, wherein R9 is
wherein n is an integer from 0 to 20.

### Claim 5 (depends on 4)

The method of claim 4, wherein n is 4 or 6.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein R10 is hydrogen.

### Claim 8 (depends on 1)

The method of claim 1, wherein the compound is

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The method of claim 1, further comprising administering to the subject an anti-viral, an anti-bacterial, or an anti-fungal agent.

### Claim 11 (depends on 1)

The method of claim 1, wherein the sexually transmitted infection is selected from the group consisting of a viral infection, a bacterial infection, and a fungal infection.

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

A method of treating or preventing a sexually transmitted infection in a subject, the method comprising administering to the subject a semen-derived enhancer of viral infection (SEVI)-binding small molecule, wherein the SEVI-binding small molecule comprises a hydrophobic molecule, wherein the hydrophobic molecule incorporates into and binds the SEVI-fibrils.

### Claim 16 (depends on 15)

The method of claim 15, further comprising administering to the subject an anti-viral, an anti-bacterial, or an anti-fungal agent.

### Claim 17 (depends on 15)

The method of claim 15, wherein the sexually transmitted infection is selected from the group consisting of a viral infection, a bacterial infection, and a fungal infection.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

A method of treating or preventing a sexually transmitted infection in a subject, the method comprising administering to the subject a semen-derived enhancer of viral infection (SEVI)-binding small molecule, wherein the SEVI-binding small molecule comprises an anionic polypeptide supramolecular assembly.

### Claim 22 (depends on 21)

The method of claim 21, further comprising administering to the subject an anti-viral, an anti-bacterial, or an anti-fungal agent.

### Claim 23 (depends on 21)

The method of claim 21, wherein the sexually transmitted infection is selected from the group consisting of a viral infection, a bacterial infection, and a fungal infection.

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27 (depends on 21)

The method of claim 21, wherein the anionic polypeptide supramolecular assembly is water-soluble.

### Claim 28 (depends on 21)

The method of claim 21, wherein the anionic polypeptide supramolecular assembly comprises a soluble hydrogel and other supramolecular assemblies derived from an Ac-(XEXE)n-NH2 (SEQ ID NO:14) polypeptide and related polypeptides.

### Claim 29 (depends on 15)

The method of claim 15, wherein the SEVI-binding small molecule further comprises a bulky side chain, a negatively charged side chain, a coupled moiety, and an antiviral molecule.

### Claim 30 (depends on 29)

The method of claim 29, wherein the bulky side chain is poly-ethylene glycol.

### Claim 31 (depends on 29)

The method of claim 29, wherein the antiviral molecule comprises pradimicin A or AZT.

### Claim 32

A pharmaceutical composition comprising:
(a) a first agent, wherein the agent comprises a SEVI-binding agent comprising a compound of the following formula:
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R1, R2, R3, R4, R5, R6, R7, and R8 are each independently selected from hydrogen, halogen, hydroxyl, trifluoromethyl, substituted or unsubstituted thio, substituted or unsubstituted alkoxyl, substituted or unsubstituted aryloxyl, substituted or unsubstituted amino, substituted or unsubstituted C1-12 alkyl, substituted or unsubstituted C2-12 alkenyl, substituted or unsubstituted C2-12 alkynyl, substituted or unsubstituted C1-12 heteroalkyl, substituted or unsubstituted C2-12 heteroalkenyl, substituted or unsubstituted C2-12 heteroalkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
R9 and R10 are each independently selected from hydrogen, substituted or unsubstituted C1-20 alkyl, substituted or unsubstituted C2-20 alkenyl, substituted or unsubstituted C2-20 alkynyl, substituted or unsubstituted C1-20 heteroalkyl, substituted or unsubstituted C2-20 heteroalkenyl, substituted or unsubstituted C2-20 heteroalkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
(b) a second agent selected from the group consisting of an anti-viral, an anti-bacterial, or an anti-fungal agent.

### Claim 33 (depends on 32)

The pharmaceutical composition of claim 32, wherein R3 is methyl.

### Claim 34 (depends on 32)

The pharmaceutical composition of claim 32, wherein R1, R2, R4, R5, R6, R7, and R8 are hydrogen.

### Claim 35 (depends on 32)

The pharmaceutical composition of claim 32, wherein R9 is
wherein n is an integer from 0 to 20.

### Claim 36 (depends on 35)

The pharmaceutical composition of claim 35, wherein n is 4 or 6.

### Claim 37

(canceled)

### Claim 38 (depends on 32)

The pharmaceutical composition of claim 32, wherein R10 is hydrogen.

### Claim 39 (depends on 32)

The pharmaceutical composition of claim 32, wherein the compound is

### Claim 40

(canceled)

### Claim 41

A pharmaceutical composition comprising:
(a) a first agent, wherein the first agent comprises a semen-derived enhancer of viral infection (SEVI)-binding small molecule, wherein the SEVI-binding small molecule comprises a hydrophobic molecule, wherein the hydrophobic molecule incorporates into and binds the SEVI-fibrils.
(b) a second agent selected from the group consisting of an anti-viral, an anti-bacterial, and an anti-fungal agent.

### Claim 42

A pharmaceutical composition comprising:
(a) a first agent, wherein the agent comprises a semen-derived enhancer of viral infection (SEVI)-binding small molecule, wherein the SEVI-binding small molecule comprises an anionic polypeptide supramolecular assembly.
(b) a second agent selected from the group consisting of an anti-viral, an anti-bacterial, and an anti-fungal agent.

### Claim 43 (depends on 42)

The pharmaceutical composition of claim 42, wherein the anionic polypeptide supramolecular assembly is water-soluble.

### Claim 44 (depends on 42)

The pharmaceutical composition of claim 42, wherein the anionic polypeptide supramolecular assembly comprises a soluble hydrogel and other supramolecular assemblies derived from an Ac-(XEXE)n-NH2 (SEQ ID NO:14) polypeptide and related polypeptides.

### Claim 45 (depends on 41)

The pharmaceutical composition of claim 41, wherein the SEVI-binding small molecule further comprises a bulky side chain, a negatively charged side chain, a coupled moiety, and an antiviral molecule.

### Claim 46 (depends on 45)

The pharmaceutical composition of claim 45, wherein the bulky side chain is poly-ethylene glycol (PEG).

### Claim 47 (depends on 45)

The pharmaceutical composition of claim 45, wherein the antiviral molecule comprises pradimicin A or AZT.
